Craig Malzahn - 13 Mar 2025 Form 3 Insider Report for REGENXBIO Inc. (RGNX)

Role
Chief Technology Officer
Signature
/s/ Patrick J. Christmas as attorney-in-fact
Issuer symbol
RGNX
Transactions as of
13 Mar 2025
Net transactions value
$0
Form type
3
Filing time
24 Mar 2025, 19:02:44 UTC
Next filing
03 Sep 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding RGNX Common Stock 17,819 13 Mar 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RGNX Stock Options (Right to buy) 13 Mar 2025 Common Stock 31,200 $40.68 Direct F2
holding RGNX Stock Options (Right to buy) 13 Mar 2025 Common Stock 9,600 $44.97 Direct F2
holding RGNX Stock Options (Right to buy) 13 Mar 2025 Common Stock 9,600 $34.31 Direct F3
holding RGNX Stock Options (Right to buy) 13 Mar 2025 Common Stock 19,130 $22.25 Direct F4
holding RGNX Stock Options (Right to buy) 13 Mar 2025 Common Stock 12,750 $18.34 Direct F5
holding RGNX Stock Options (Right to buy) 13 Mar 2025 Common Stock 33,150 $7.86 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 9,988 shares of common stock underlying time-based restricted stock units.
F2 As of the date of this report these options are fully vested and exercisable.
F3 25% of the shares vested on January 3, 2023. The balance will vest in equal monthly installments over the 36 months following January 3, 2023 while the optionee provides continuous service to the Issuer.
F4 25% of the shares subject to this option vested on January 3, 2024. The balance will vest in equal monthly installments over the 36 months following January 3, 2024 while the optionee provides continuous service to the Issuer.
F5 25% of the shares subject to this option vested on January 3, 2025. The balance will vest in equal monthly installments over the 36 months following January 3, 2025 while the optionee provides continuous service to the Issuer.
F6 25% of the shares subject to this option shall vest on January 3, 2026. The balance will vest in equal monthly installments over the 36 months following January 3, 2026 while the optionee provides continuous service to the Issuer.

Remarks:

EXHIBIT LIST - Exhibit 24 - Power of Attorney for Craig Malzahn